Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
Informe.
http://investor.thresholdpharm.com/secfiling.cfm?filingid=1144204-13-25829
The net loss for the first quarter of 2013 was $9.2 million compared to a net loss of $115.5 million for the first quarter of 2012.
Threshold recognized revenue of $2.9 million in the first quarter of 2013 compared to $0.3 million in first quarter of 2012
During the first quarter of 2013 Threshold earned a $30 million milestone payment related to the initiation of a global Phase 3 study of TH-302 in combination with gemcitabinea. To date, the Company has received $97.5 million in upfront and milestone payments.
PS: Tengo que salir pitando.
«Después de nada, o después de todo/ supe que todo no era más que nada.»